Sarcode Bioscience Inc.

Omeros Corporation

Novartis Pharmaceuticals Corporation

Imago Biosciences, Inc.

Cenerx Biopharma, Inc.

Elisabeth C A Brot

James Robert Zeller

Michael Hall

Sripathy Venkatraman

Subashree Iyer

Jennifer Lynn Gage

Thomas L Little, Jr

Wayne Douglas Luke

Neil S Cutshall

Karl Reineke

Marco Jonas

Michael James McDermott

John Michael McCall

Arthur Glenn Romero

He Zhao

Jennifer Leigh Nelson

Ekaterina Albert

Paul Isbester

Cassandra Celatka

Grant Jackson Palmer

Amy E Tapper

Christopher Scott Seadeek

Jian-Xie Chen

Xuemei Chen

Xufeng Sun

Zhihua Li

Xiaoming Liao

Suba Iyer

Daniel K Keefe, Jr

Brian P Haney

Nigel Metcalfe

Toni Chancellor

Betina Biolatto

Provided in this disclosure are methods for the synthesis of substituted 2-arylcyclopropylamines and 2-heteroarylcyclopropylamines and related compounds. Also provided are methods for reduction of thioesters to aldehydes, and methods for reductive animation of cyclopropylamines.

Methods and processes for the preparation of KDM1A inhibitors

Methods of preparation and purification of a compound of Formula I, intermediates thereof, a polymorph thereof, and related compounds are disclosed. Formulations and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed. 

LFA-1 inhibitor and methods of preparation and polymorph thereof

The invention relates to a novel variable hydrate crystalline form of 1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, methods for the preparation thereof, pharmaceutical compositions thereof and their use in the inhibition of PDE10.

Solid state forms of a PDE10 inhibitor

The present invention is directed to an improved process for the preparation of compounds of Formula (II) and Formula (III), which are useful in the inhibition of PDE10. In particular, the present invention is directed to an improved process for the preparation of 1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, which is useful in the inhibition of PDE10.

Processes and intermediates for the preparation of a PDE10 inhibitor

Provided herein is a new form of 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathin 10,10-dioxide, which demonstrates higher stability relative to other forms of 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin-10,10-dioxide. In particular, this new form affords less dosage critical administration of 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathin 10,10-dioxide relative to other forms. The new solid form of 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin-10,10-dioxide has been determined and is provided herein. This new solid form of 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin-10,10-dioxide can be characterized by any of a number of its properties, including, but not limited to, melting point, differential scanning calorimetry, infrared spectroscopic spectrum or portions thereof, solubility, methods and conditions under which this form is prepared, and/or precipitated from solution, and, when in crystalline form, the crystalline form can be characterized according to the diffraction pattern or portions thereof.

Polymorphic form of fluoro-7-(2,2,2-trifluoroethoxy) phenoxathiin-10,10-dioxide

Growing community of inventors

Albany, NY, United States of America

Elisabeth C A Brot